Sun Pharma 和 Moebius Medical 获得非阿片类骨关节炎膝关节疼痛治疗 MM-II 的快速通道指定。 Sun Pharma and Moebius Medical receive Fast Track designation for non-opioid osteoarthritis knee pain treatment MM-II.
Sun Pharma 和 Moebius Medical 已获得 FDA 的 MM-II 快速通道指定，MM-II 是一种用于治疗骨关节炎膝关节疼痛的非阿片类药物。 Sun Pharma and Moebius Medical have received Fast Track designation from the FDA for MM-II, a non-opioid treatment for osteoarthritis knee pain. 这一产品使用独特的大型脂质悬浮剂,旨在减少联合摩擦和痛苦。 This product employs a unique suspension of large liposomes aimed at reducing joint friction and pain. " 快车道 " 方案为快速审查和批准严重状况提供了便利。 The Fast Track program facilitates quicker review and approval processes for serious conditions. 这些公司计划开始第3阶段的试验,并在欧盟进行CE标记。 The companies plan to begin Phase 3 trials and pursue a CE Mark in the EU.